Yunchao Huang

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

James Chih‐Hsin Yang, Yi‐Long Wu, Martin Schüler et al. · The Lancet Oncology · 2015 · 1.6K citations

Lux-lung 3, Lux-lung 6, Medicine +9

Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial

Caicun Zhou, Gongyan Chen, Yunchao Huang et al. · The Lancet Respiratory Medicine · 2020 · 488 citations

Oncology, Clinical Trials, Chemotherapy-naive Patients +9

Clinical characteristics and medical service utilization of lung cancer in China, 2005–2014: Overall design and results from a multicenter retrospective epidemiologic survey

Jufang Shi, Le Wang, Ning Wu et al. · Lung Cancer · 2018 · 132 citations

Medical Service Utilization, Oncology, Cancer Epidemiology +10

<scp>C</scp>hina national lung cancer screening guideline with low‐dose computed tomography (2015 version)

Qinghua Zhou, Ya‐guang Fan, Hong Bu et al. · Thoracic Cancer · 2015 · 88 citations · Full text

LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung.

Yi‐Long Wu, Caicun Zhou, Chengping Hu et al. · Journal of Clinical Oncology · 2013 · 83 citations

Pathology, Oncology, Gc Arms +17